Effects of once-weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN-6 trial.
Diabetes, obesity & metabolism20232 citationsPMID: 36514266
Kolkailah, Ahmed A; Lingvay, Ildiko; Dobrecky-Mery, Idit; Aharonovich, Alona; David, Jens-Peter; Holse, Cecilie; Rasmussen, Søren; McGuire, Darren K
Effects of once-weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN-6 trial. | Pepdox